Tag Archives: ZFGN

Analysts Offer Insights on Healthcare Companies: Zafgen (NASDAQ: ZFGN) and Pharming Group (Other OTC: PHGUF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zafgen (ZFGN – Research Report) and Pharming Group (PHGUF – Research Report). Zafgen (ZFGN) Cowen & Co. analyst Yaron Werber maintained a Hold rating on

Cowen & Co. Maintains a Hold Rating on Zafgen (ZFGN)

In a report released today, Yaron Werber from Cowen & Co. maintained a Hold rating on Zafgen (ZFGN – Research Report). The company’s shares opened today at $2.29, close to its 52-week low of $1.88. According to TipRanks.com, Werber is

Wedbush Thinks Zafgen’s Stock is Going to Recover

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Zafgen (ZFGN – Research Report), with a price target of $6. The company’s shares opened today at $2.29, close to its 52-week low of $1.88. According

Wedbush Keeps Their Buy Rating on Zafgen (ZFGN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Zafgen (ZFGN – Research Report) yesterday and set a price target of $6. The company’s shares closed yesterday at $2.61, close to its 52-week low of $2.33. According to TipRanks.com, Moussatos

Cowen & Co. Sticks to Their Hold Rating for Zafgen (ZFGN)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Zafgen (ZFGN – Research Report). The company’s shares opened today at $4.98, close to its 52-week low of $4.51. According to TipRanks.com, Nadeau is

Analysts Offer Insights on Healthcare Companies: Zafgen (NASDAQ: ZFGN) and Merrimack Pharmaceuticals (NASDAQ: MACK)

Analysts fell to the sidelines weighing in on Zafgen (NASDAQ: ZFGN) and Merrimack Pharmaceuticals (NASDAQ: MACK) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks. Zafgen (NASDAQ: ZFGN) Cowen & Co. analyst Phil Nadeau maintained